Search Results 91-100 of 16892 for Antagonist

  1. Study Using Chromogranin A As Surveillance Biomarker In Patients With CARcinoids - Mayo Clinic

    H2-receptor antagonists. Baseline ECOG PS < 2. Written informed consent signed. Exclusion Criteria: Other active malignancy with the exclusion of melanoma ...

  2. HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial (HIP ATTACK-2) - Mayo Clinic

    patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT); 3. patients with peri-prosthetic fracture, open ...

  3. Gregory W. Barsness, M.D. - Doctors and Medical Staff - Mayo Clinic

    MemberClinical Events Committee, Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network. 1997.

  4. Primary aldosteronism: The role of adrenal venous sampling - Mayo Clinic

    Patients with IHA should be treated not surgically but medically with a mineralocorticoid receptor antagonist. Therefore, determining the subtype of PA (APA ...

  5. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC - Mayo Clinic

    start of study therapy or after 45 days whatever happens first. - If received, prior LHRH agonist/antagonist with or without first generation anti-androgen ...

  6. Uterine fibroids - Diagnosis and treatment - Mayo Clinic

    Gonadotropin-releasing hormone (GnRH) antagonists. These medicines can treat heavy menstrual bleeding in people with uterine fibroids who haven't gone ...

  7. Holly L. Geyer, M.D. - Doctors and Medical Staff - Mayo Clinic

    MemberOpioid Antagonist Procurement Subcommittee, School Training Overdose Preparedness and Intelligence Taskforce (STOP-IT), Arizona Department of Education.

  8. An Extension Study Monitoring the Safety of Patients with Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 - Mayo Clinic

    Use of TNF antagonists;; Use of antagonists of IL-12 ± IL-23 (e.g., ustekinumab);; Immunization with a live/attenuated vaccine;; Use of anti-adhesion molecules ...

  9. Tofacitinib is first oral medication approved for use in treating moderate to severe ulcerative colitis - Mayo Clinic

    "The efficacy of this JAK antagonist was pretty impressive in the pivotal trials — the maintenance data in particular — with very large differences between ...

  10. Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough - Mayo Clinic

    Participation eligibility · Prior treatment with serlopitant or other NK1-R antagonist · Presence of any medical condition or disability that could interfere with ...